Compare · ALMR vs RVTY
ALMR vs RVTY
Side-by-side comparison of Alamar Biosciences Inc. (ALMR) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALMR and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $12.32B, about 6.9x ALMR ($1.79B).
- Over the past year, ALMR is up 17.7% and RVTY is up 6.6% - ALMR leads by 11.1 points.
- ALMR has been more active in the news (6 items in the past 4 weeks vs 4 for RVTY).
- RVTY has more recent analyst coverage (20 ratings vs 5 for ALMR).
PerformanceALMR+17.68%RVTY+17.54%
2026-04-17+0.00%2026-07-24
- Company
- Alamar Biosciences Inc.
- Revvity Inc.
- Price
- $26.12+1.81%
- $110.45-2.40%
- Market cap
- $1.79B
- $12.32B
- 1M return
- +9.59%
- +4.51%
- 1Y return
- +17.68%
- +6.56%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 6
- 4
- Recent ratings
- 5
- 20
Latest ALMR
- SEC Form 8-K filed by Alamar Biosciences Inc.
- Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
- Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
- Amendment: SEC Form SCHEDULE 13D/A filed by Alamar Biosciences Inc.
- Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
- SEC Form SCHEDULE 13G filed by Alamar Biosciences Inc.
- Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
- Analyst initiated coverage on Alamar Biosciences with a new price target
- BofA Securities initiated coverage on Alamar Biosciences with a new price target
- TD Cowen initiated coverage on Alamar Biosciences with a new price target
Latest RVTY
- Vice President and CAO Gonzales Anita sold $9,306 worth of shares (85 units at $109.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,201 units (SEC Form 4)
- Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
- Revvity to Hold Earnings Call on Tuesday, August 4, 2026
- Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
- Bernstein resumed coverage on Revvity with a new price target
- SEC Form 11-K filed by Revvity Inc.
- Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
- Vice President and CAO Gonzales Anita covered exercise/tax liability with 33 shares, decreasing direct ownership by 0.45% to 7,286 units (SEC Form 4) to cover taxes
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.